Ascorbate with Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 36
- Registration Number
- NCT06083454
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 30
- Registration Number
- NCT04699838
- Locations
- 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
PDR001 + Panobinostat for Melanoma and NSCLC
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Muhammad Furqan
- Registration Number
- NCT03982134
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
Terminated
- Conditions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 29
- Registration Number
- NCT03951012
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 32
- Registration Number
- NCT02769832
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
© Copyright 2024. All Rights Reserved by MedPath